Discrepancy between treatment goals documentation by oncologists and their understanding among cancer patients.

Monga, Varun; Kaleem, Hassan; Mott, Sarah C; Button, Anna M.; Zamba, Gideon; Milhem, Mohammed M.

doi:10.1200/jco.2015.33.15_suppl.e20574

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is difficult to know whether the clinician's recommendation included consideration of the trade‐off between risk and benefit, for that particular patient. Several studies have shown a discrepancy between clinicians’ perceived goal of therapy versus that of the patient ; consequently, it would be bold to assume the clinicians were fully aware of any patient's values and preferences when discussing treatment options. The patients’ low recall of both efficacy and toxicity information in our study suggests clinicians may need a range of techniques to aid their communication and highlights the need for individualized educational resources.…”

Section: Discussionmentioning

confidence: 99%

Balancing the Hype with Reality: What Do Patients with Advanced Melanoma Consider When Making the Decision to Have Immunotherapy?

2019

View full text Add to dashboard Cite

Background Immunotherapy has resulted in unprecedented improvements in survival and maintained quality of life for many patients with advanced melanoma. However, durable responses are observed in only a minority of patients, and severe treatment side effects are experienced by 5%–30%. There are no reliable tests that can differentiate between patients who are likely to respond to immunotherapy and those who will not. Hence, new challenges have arisen as clinicians try to facilitate patients in their decision‐making regarding immunotherapy. Furthermore, little is known about the real‐world patients’ experience and understanding of immunotherapy outside the clinical trial setting. Here, we explore the perspectives of patients undergoing immunotherapy for melanoma and focus on factors that influenced their treatment decision‐making. Materials and Methods Twenty‐three in‐depth semistructured interviews were conducted with patients receiving pembrolizumab for stage IV melanoma at an Australian public cancer hospital. Patients were recruited at a range of time points after commencing therapy, and their experience of treatment was explored. Interviews were audio recorded, transcribed verbatim, coded, and analyzed thematically. Results Immunotherapy is viewed as a symbol of hope, with high‐profile anecdotes reinforcing this perception. Only a minority of patients expressed a good understanding of the likely efficacy and potential treatment side effects. Patients are reliant on their clinicians’ recommendation regarding immunotherapy treatment decisions. Conclusion Novel treatments such as immunotherapy provide significant hope for patients. This may influence their preference for immunotherapy over and above the usual considerations of the trade‐off between efficacy and toxicity. Careful counsel and individualized patient resources may further facilitate treatment decision‐making. Implications for Practice This study highlighted some of the misconceptions held by patients that need to be addressed when discussing the possibility of receiving treatment with immunotherapy for advanced melanoma. Patients placed a lot of importance on high‐profile anecdotes rather than truly understanding likely outcomes of treatment based on personal circumstances. The majority of patients had a poor understanding of the potential side effects and long‐term implications of treatment with immunotherapy. Careful counsel is required in order to facilitate informed decision‐making about treatment and to ensure possible side effects are known and appreciated. Further research is needed to develop tools to aid decision‐making in everyday clinical practice.

show abstract

Section: Discussionmentioning

confidence: 99%